Apolipoprotein AII amyloidosis

WikiDoc Resources for Apolipoprotein AII amyloidosis
Articles
Most recent articles on Apolipoprotein AII amyloidosis Most cited articles on Apolipoprotein AII amyloidosis Review articles on Apolipoprotein AII amyloidosis Articles on Apolipoprotein AII amyloidosis in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Apolipoprotein AII amyloidosis Images of Apolipoprotein AII amyloidosis Photos of Apolipoprotein AII amyloidosis Podcasts & MP3s on Apolipoprotein AII amyloidosis Videos on Apolipoprotein AII amyloidosis
Evidence Based Medicine
Cochrane Collaboration on Apolipoprotein AII amyloidosis Bandolier on Apolipoprotein AII amyloidosis TRIP on Apolipoprotein AII amyloidosis
Clinical Trials
Ongoing Trials on Apolipoprotein AII amyloidosis at Clinical Trials.gov Trial results on Apolipoprotein AII amyloidosis Clinical Trials on Apolipoprotein AII amyloidosis at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Apolipoprotein AII amyloidosis NICE Guidance on Apolipoprotein AII amyloidosis NHS PRODIGY Guidance FDA on Apolipoprotein AII amyloidosis CDC on Apolipoprotein AII amyloidosis
Books
Books on Apolipoprotein AII amyloidosis
News
Apolipoprotein AII amyloidosis in the news Be alerted to news on Apolipoprotein AII amyloidosis News trends on Apolipoprotein AII amyloidosis
Commentary
Blogs on Apolipoprotein AII amyloidosis
Definitions
Definitions of Apolipoprotein AII amyloidosis
Patient Resources / Community
Patient resources on Apolipoprotein AII amyloidosis Discussion groups on Apolipoprotein AII amyloidosis Patient Handouts on Apolipoprotein AII amyloidosis Directions to Hospitals Treating Apolipoprotein AII amyloidosis Risk calculators and risk factors for Apolipoprotein AII amyloidosis
Healthcare Provider Resources
Symptoms of Apolipoprotein AII amyloidosis Causes & Risk Factors for Apolipoprotein AII amyloidosis Diagnostic studies for Apolipoprotein AII amyloidosis Treatment of Apolipoprotein AII amyloidosis
Continuing Medical Education (CME)
CME Programs on Apolipoprotein AII amyloidosis
International
Apolipoprotein AII amyloidosis en Espanol Apolipoprotein AII amyloidosis en Francais
Business
Apolipoprotein AII amyloidosis in the Marketplace Patents on Apolipoprotein AII amyloidosis
Experimental / Informatics
List of terms related to Apolipoprotein AII amyloidosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Fahimeh Shojaei, M.D.

Synonyms and keywords:

Historical Perspective

• In 1639, Nicolaus Fontanus autopsied a young man who had ascites, jaundice, liver abscess, and splenomegaly and his report has been the first description of amyloidosis.
• In 1854, Rudolph Virchow introduced the term "amyloid" as a macroscopic abnormality in some tissues.
• In 1867, Weber reported the first case of amyloidosis associated with multiple myeloma.
• In 1922, Bennhold introduced Congo Red staining of amyloid that remains the gold standard for diagnosis.
• In 1959, Cohen and Calkins used ultrathin sections of amyloidotic tissues and assessed by electron microscopy, explained the presence of non-branching fibrils with indeterminate length and variable width.

Classification

Apolipoprotein AII amyloidosis is one of the subtypes of familial amyloidosis. Familiar amyloidosis may be classified according to the type of mutant protein into 7 subtypes:

• Transthyretin (TTR)
• Apolipoprotein AI
• Apolipoprotein AII
• Fibrinogen Aa
• Lysozyme
• Gelsolin
• Cystatin C

Genes involved in familial amyloidosis

Transthyretin (TTR)

Apolipoprotein AI

Gelsolin

Lysozyme

Cystatin C

Fibrinogen Aa-chain

Apolipoprotein AII

Pathophysiology

Pathogenesis

• It is understood that amyloidosis is the result of deposition of Amyloid.
• Amyloid is an abnormal insoluble extracellular protein which may cause organic dysfunction and a wide variety of clinical syndromes.
• These abnormal amyloids are derived from misfolding and aggregation of normally soluble proteins.
• Amyloid depositions also have glycosaminoglycans and serum amyloid P component (SAP) which alter the propensity for amyloid formation.
• Amyloid deposition can disrupt tissue structure of involved organ and consequently leads to organ failure.
• Genetic mutations in Apolipoprotein AII gene may lead to misfolding protein product.

Genetics

• 3 different mutations in the stop codon for the ApoAII gene including stop78Gly, stop78Ser, and stop78Arg has been found to be associated with amyloidosis.
• These mutations lead to an extra 21-amino acid at the carboxyl terminal end of the protein.

Causes

Common cause of Apolipoprotein AII amyloidosis is genetic mutation.

Differentiating ((Page name)) from Other Diseases

[Disease name] must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as [differential dx1], [differential dx2], and [differential dx3].

OR

[Disease name] must be differentiated from [[differential dx1], [differential dx2], and [differential dx3].

Epidemiology and Demographics

• The incidence of amyloidosis is approximately 1.2 per 100,000 individuals per year worldwide.

• The mortality rate of systemic amyloidosis is approximately 100 per 100,000 deaths in developed countries.

• In apolipoprotein AII amyloidosis, the mean age of presentation is early adulthood.

• Hereditary amyloidosis subtypes include a substitution of an amino acid that is detected in approximately 4% of the african american population.

• Men are more commonly affected by amyloidosis than women.

Risk Factors

There are no established risk factors for [disease name].

OR

The most potent risk factor in the development of [disease name] is [risk factor 1]. Other risk factors include [risk factor 2], [risk factor 3], and [risk factor 4].

OR

Common risk factors in the development of [disease name] include [risk factor 1], [risk factor 2], [risk factor 3], and [risk factor 4].

OR

Common risk factors in the development of [disease name] may be occupational, environmental, genetic, and viral.

Screening

There is insufficient evidence to recommend routine screening for [disease/malignancy].

OR

According to the [guideline name], screening for [disease name] is not recommended.

OR

According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with [condition 1], [condition 2], and [condition 3].

Natural History, Complications, and Prognosis

If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].

OR

Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].

OR

Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [#]%.

Diagnosis

Diagnostic Study of Choice

The diagnosis of [disease name] is made when at least [number] of the following [number] diagnostic criteria are met: [criterion 1], [criterion 2], [criterion 3], and [criterion 4].

OR

The diagnosis of [disease name] is based on the [criteria name] criteria, which include [criterion 1], [criterion 2], and [criterion 3].

OR

The diagnosis of [disease name] is based on the [definition name] definition, which includes [criterion 1], [criterion 2], and [criterion 3].

OR

There are no established criteria for the diagnosis of [disease name].

History and Symptoms

The majority of patients with [disease name] are asymptomatic.

OR

The hallmark of [disease name] is [finding]. A positive history of [finding 1] and [finding 2] is suggestive of [disease name]. The most common symptoms of [disease name] include [symptom 1], [symptom 2], and [symptom 3]. Common symptoms of [disease] include [symptom 1], [symptom 2], and [symptom 3]. Less common symptoms of [disease name] include [symptom 1], [symptom 2], and [symptom 3].

Physical Examination

Patients with [disease name] usually appear [general appearance]. Physical examination of patients with [disease name] is usually remarkable for [finding 1], [finding 2], and [finding 3].

OR

Common physical examination findings of [disease name] include [finding 1], [finding 2], and [finding 3].

OR

The presence of [finding(s)] on physical examination is diagnostic of [disease name].

OR

The presence of [finding(s)] on physical examination is highly suggestive of [disease name].

Laboratory Findings

An elevated/reduced concentration of serum/blood/urinary/CSF/other [lab test] is diagnostic of [disease name].

OR

Laboratory findings consistent with the diagnosis of [disease name] include [abnormal test 1], [abnormal test 2], and [abnormal test 3].

OR

[Test] is usually normal among patients with [disease name].

OR

Some patients with [disease name] may have elevated/reduced concentration of [test], which is usually suggestive of [progression/complication].

OR

There are no diagnostic laboratory findings associated with [disease name].

Electrocardiogram

There are no ECG findings associated with [disease name].

OR

An ECG may be helpful in the diagnosis of [disease name]. Findings on an ECG suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].

X-ray

There are no x-ray findings associated with [disease name].

OR

An x-ray may be helpful in the diagnosis of [disease name]. Findings on an x-ray suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].

OR

There are no x-ray findings associated with [disease name]. However, an x-ray may be helpful in the diagnosis of complications of [disease name], which include [complication 1], [complication 2], and [complication 3].

Echocardiography or Ultrasound

There are no echocardiography/ultrasound findings associated with [disease name].

OR

Echocardiography/ultrasound may be helpful in the diagnosis of [disease name]. Findings on an echocardiography/ultrasound suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].

OR

There are no echocardiography/ultrasound findings associated with [disease name]. However, an echocardiography/ultrasound may be helpful in the diagnosis of complications of [disease name], which include [complication 1], [complication 2], and [complication 3].

CT scan

There are no CT scan findings associated with [disease name].

OR

[Location] CT scan may be helpful in the diagnosis of [disease name]. Findings on CT scan suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].

OR

There are no CT scan findings associated with [disease name]. However, a CT scan may be helpful in the diagnosis of complications of [disease name], which include [complication 1], [complication 2], and [complication 3].

MRI

There are no MRI findings associated with [disease name].

OR

[Location] MRI may be helpful in the diagnosis of [disease name]. Findings on MRI suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].

OR

There are no MRI findings associated with [disease name]. However, a MRI may be helpful in the diagnosis of complications of [disease name], which include [complication 1], [complication 2], and [complication 3].

Other Imaging Findings

There are no other imaging findings associated with [disease name].

OR

[Imaging modality] may be helpful in the diagnosis of [disease name]. Findings on an [imaging modality] suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].

Other Diagnostic Studies

There are no other diagnostic studies associated with [disease name].

OR

[Diagnostic study] may be helpful in the diagnosis of [disease name]. Findings suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].

OR

Other diagnostic studies for [disease name] include [diagnostic study 1], which demonstrates [finding 1], [finding 2], and [finding 3], and [diagnostic study 2], which demonstrates [finding 1], [finding 2], and [finding 3].

Treatment

Medical Therapy

There is no treatment for [disease name]; the mainstay of therapy is supportive care.

OR

Supportive therapy for [disease name] includes [therapy 1], [therapy 2], and [therapy 3].

OR

The majority of cases of [disease name] are self-limited and require only supportive care.

OR

[Disease name] is a medical emergency and requires prompt treatment.

OR

The mainstay of treatment for [disease name] is [therapy].

OR   The optimal therapy for [malignancy name] depends on the stage at diagnosis.

OR

[Therapy] is recommended among all patients who develop [disease name].

OR

Pharmacologic medical therapy is recommended among patients with [disease subclass 1], [disease subclass 2], and [disease subclass 3].

OR

Pharmacologic medical therapies for [disease name] include (either) [therapy 1], [therapy 2], and/or [therapy 3].

OR

Empiric therapy for [disease name] depends on [disease factor 1] and [disease factor 2].

OR

Patients with [disease subclass 1] are treated with [therapy 1], whereas patients with [disease subclass 2] are treated with [therapy 2].

Surgery

Surgical intervention is not recommended for the management of [disease name].

OR

Surgery is not the first-line treatment option for patients with [disease name]. Surgery is usually reserved for patients with either [indication 1], [indication 2], and [indication 3]

OR

The mainstay of treatment for [disease name] is medical therapy. Surgery is usually reserved for patients with either [indication 1], [indication 2], and/or [indication 3].

OR

The feasibility of surgery depends on the stage of [malignancy] at diagnosis.

OR

Surgery is the mainstay of treatment for [disease or malignancy].

Primary Prevention

There are no established measures for the primary prevention of [disease name].

OR

There are no available vaccines against [disease name].

OR

Effective measures for the primary prevention of [disease name] include [measure1], [measure2], and [measure3].

OR

[Vaccine name] vaccine is recommended for [patient population] to prevent [disease name]. Other primary prevention strategies include [strategy 1], [strategy 2], and [strategy 3].

Secondary Prevention

There are no established measures for the secondary prevention of [disease name].

OR

Effective measures for the secondary prevention of [disease name] include [strategy 1], [strategy 2], and [strategy 3].

References

Template:WikiDoc Sources